What I see repeatedly in board-level discussions is organisations pouring resource into the visible pillars of metabolic risk — obesity, hypertension, diabetes, cholesterol — while a major driver of downstream harm sits largely untracked. Liver health is that blind spot. In the UK, liver disease remains one of the leading causes of preventable illness and premature death, yet it is still rarely integrated into workforce risk models in the way other metabolic markers are. That omission is not just clinically incomplete; it is commercially shortsighted.
The blind spot in metabolic risk
I have long argued that organisations over-focus on what is easiest to measure rather than what is most consequential. Liver dysfunction occupies precisely that gap. It develops quietly, is tightly linked to obesity, diabetes, alcohol consumption and inactivity, and can progress significantly before symptoms force attention. This matters because metabolic risk is never only a health story; it is an absence, presenteeism, insurance cost and long-term capability story.
The clinical world is already moving. A 2026 editorial in the American Journal of Preventive Cardiology makes the case that liver pathology should be incorporated into cardiometabolic risk models. It reflects cumulative metabolic, inflammatory, fibrotic and haemodynamic stress, and non-invasive liver measures can help identify individuals who appear lower-risk under conventional staging. If the medical model is shifting in this direction, workforce risk models should not lag behind.
Why the liver matters to employers
For HR and occupational health teams, the practical issue is not universal liver screening. It is that a significant share of metabolic risk may be misclassified when liver health is omitted from the assessment. Both the NHS and the UK Government recognise liver disease as a public health priority. The Government’s liver disease profile continues to show elevated mortality patterns, with age-standardised rates remaining concerning in recent updates.
Finance and risk leaders should pay attention for three clear reasons. First, liver disease is frequently preventable or modifiable, creating a genuine risk-management opportunity rather than an unavoidable cost. The British Liver Trust has stated that 90% of adult liver disease cases are preventable, with excess alcohol, obesity, poor diet and viral hepatitis among the main drivers. Second, the condition is often silent until advanced, meaning a workforce can carry substantial risk without obvious operational signals. Third, liver disease overlaps with the same factors already driving claims and long-term absence across metabolic, cardiovascular and mental health pathways.
The commercial case for risk integration
Too many organisations still treat liver health as a specialist clinical matter rather than a marker within a broader risk architecture. This is a mistake. Metabolic risk rarely arrives in isolation; it clusters across lifestyle, medication, sleep, stress, alcohol use and socioeconomic factors.
From a business perspective, liver-related risk functions as a proxy for hidden fragility. An employee may perform adequately today while underlying liver dysfunction progresses, leaving the organisation exposed to future liabilities in productivity, absence, healthcare utilisation and potentially disability claims. Incorporating liver health into the model does not mean medicalising the workforce. It means improving the ability to identify cohorts that require earlier intervention, better signposting and more targeted prevention.
The evidence supports a shift towards non-invasive assessment. Measures such as FIB-4, ELF, vibration-controlled transient elastography and MR-based approaches can identify liver fibrosis risk without biopsy. For employers, the lesson is not to order indiscriminate scans but to recognise that liver risk can be triaged intelligently within existing health pathways.
What HR and risk miss
The most common failure I observe is fragmentation. Health strategies often silo alcohol support, obesity programmes, diabetes management and cardiovascular risk, even though they frequently form part of the same underlying pattern. The result is a false sense of coverage. An employee can participate in weight management and alcohol programmes yet remain invisible from a hepatic risk perspective.
A second failure is over-reliance on self-disclosure. Liver risk is exactly the sort of issue employees are reluctant to raise early, especially in cultures where alcohol use is normalised or health conversations feel punitive. A third failure is treating screening as a static, annual event rather than a dynamic risk process. Metabolic risk evolves, and liver risk evolves with it; one-off checks are often too blunt to detect meaningful change in time to shift outcomes.
Strategic actions
Senior leaders do not need a new medical department. They need better risk design. In my experience, the following steps deliver the highest return:
- Integrate liver markers into existing metabolic review pathways as part of wider cardiovascular and metabolic risk stratification, rather than as stand-alone surveillance.
- Use occupational health and wellbeing data to identify clusters — obesity, diabetes, elevated alcohol use, fatty liver indicators or raised liver enzymes — and shift from generic wellness messaging to targeted case finding.
- Review benefits and provider pathways to ensure employees can access credible follow-up, including timely GP referral support, evidence-based alcohol services and weight management routes.
- Train managers and HR business partners to recognise that repeated fatigue, reduced concentration and frequent short-term absence may signal metabolic and hepatic risk alongside stress or workload issues.
- Bring this perspective into insurer and broker conversations. Organisations that demonstrate integrated metabolic risk management are better positioned to negotiate prevention-led approaches instead of purely claims-driven responses.
What this changes
For HR, the value lies in sharper prevention and improved employee experience. For Finance, it offers a more credible route to controlling avoidable costs rather than simply absorbing them. For risk leaders, it moves the organisation from broad wellbeing rhetoric to a defensible model of health vulnerability that aligns with emerging clinical thinking.
Liver health is not the whole story of metabolic risk, but it is too important to remain the missing variable. Review your current risk framework now. If hepatic health is absent from it, you are carrying an unquantified exposure that is both preventable and increasingly measurable. The organisations that close this gap first will gain the clearest advantage in workforce resilience and cost control.